Katherine L. Molnar-Kimber

2.6k citations

37 papers · 2.1k indexed · h-index 27

Genetics top 2%
- Virus-based gene therapy research 21
Biotechnology top 2%
- Cancer Research and Treatments 5
Oncology top 5%
- CAR-T cell therapy research 4
Epidemiology top 5%
- Hepatitis B Virus Studies 7
- Herpesvirus Infections and Treatments 6
Infectious Diseases top 5%
- Viral gastroenteritis research and epidemiology 5
Molecular Biology
- Signaling Pathways in Disease 5
- Viral Infectious Diseases and Gene Expression in Insects 4

Co-authors: Steven Μ. Albelda William S. Mason Larry R. Kaiser Barry M. Weichman Jesse Summers Kunjlata M. Amin Daniel H. Sterman James M. Wilson
Cited by: Genetics Biotechnology Oncology
Journals: Proceedings of the National Academy of Sciences (2 papers)Journal of the American Chemical Society (1 paper)The Journal of Experimental Medicine (2 papers)
Partner nations: United States Canada Israel

In The Last Decade

Katherine L. Molnar-Kimber

37 papers receiving 2.0k citations

Peers

Countries citing papers authored by Katherine L. Molnar-Kimber

Since Specialization

Citations

This map shows the geographic impact of Katherine L. Molnar-Kimber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine L. Molnar-Kimber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine L. Molnar-Kimber more than expected).

Fields of papers citing papers by Katherine L. Molnar-Kimber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine L. Molnar-Kimber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine L. Molnar-Kimber. The network helps show where Katherine L. Molnar-Kimber may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Katherine L. Molnar-Kimber, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Katherine L. Molnar-Kimber Line = papers co-authored together Katherine L. Molnar-Kimber links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Each type of cause that initiates rheumatoid arthritis or RA flares differentially affects the response to therapy Medical Hypotheses ·Katherine L. Molnar-Kimber,Charles T. Kimber	2011	7
2	Replication-Selective Herpes Simplex Virus Type 1 Mutant Therapy of Cervical Cancer Is Enhanced by Low-Dose Radiation Human Gene Therapy ·Stephanie V. Blank,Stephen C. Rubin,George Coukos,Kunjlata M. Amin,Steven Μ. Albelda,Katherine L. Molnar-Kimber	2002	52
3	Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy Cancer Gene Therapy ·George Coukos,Antonis Makrigiannakis,Sacha Montas,Larry R. Kaiser,Takane Toyozumi,Ivor Benjamin,Steven Μ. Albelda,Stephen C. Rubin,Katherine L. Molnar-Kimber	2000	54
4	Use of Transcriptional Regulatory Sequences of Telomerase (hTER and hTERT) for Selective Killing of Cancer Cells Molecular Therapy ·Rula Abdul‐Ghani,Patricia Ohana,Imad Matouk,Suhail Ayesh,Basim M. Ayesh,Morris Laster,O. Bibi,Hilla Giladi,Katherine L. Molnar-Kimber,Maher A. Sughayer,Natalia Sánchez de Groot,Abraham Hochberg	2000	65
5	Effect of Preexisting Anti-Herpes Immunity on the Efficacy of Herpes Simplex Viral Therapy in a Murine Intraperitoneal Tumor Model Molecular Therapy ·Eric S. Lambright,Eugene H. Kang,Seth Force,Michael Lanuti,David Caparrelli,Larry R. Kaiser,Steven M. Albelda,Katherine L. Molnar-Kimber	2000	39
6	A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma Cancer Gene Therapy ·Daniel H. Sterman,Katherine L. Molnar-Kimber,Tara Iyengar,Michael Chang,Michael Lanuti,Kunjlata M. Amin,Brandon K Pierce,Eugene Kang,Joseph Treat,Adri Recio,Leslie A. Litzky,James M. Wilson,Larry R. Kaiser,Steven M. Albelda	2000	28
7	Combination Therapy with Lamivudine and Adenovirus Causes Transient Suppression of Chronic Woodchuck Hepatitis Virus Infections Journal of Virology ·Tianlun Zhou,Juo-Tao Guo,Frederick A. Nunes,Katherine L. Molnar-Kimber,James M. Wilson,Carol E. Aldrich,Jeffry Saputelli,Sam Litwin,Lynn D. Condreay,Christoph Seeger,William S. Mason	2000	27
8	Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. PubMed ·George Coukos,Antonis Makrigiannakis,Eugene Kang,Stephen C. Rubin,Steven Μ. Albelda,Katherine L. Molnar-Kimber	2000	55
9	Oncolytic therapy using a mutant type-1 herpes simplex virus and the role of the immune system The Annals of Thoracic Surgery ·Eric S. Lambright,David Caparrelli,Abbas E. Abbas,T Toyoizumi,George Coukos,Katherine L. Molnar-Kimber,Larry R Kaiser	1999	17
10	Impact of Preexisting and Induced Humoral and Cellular Immune Responses in an Adenovirus-Based Gene Therapy Phase I Clinical Trial for Localized Mesothelioma Human Gene Therapy ·Katherine L. Molnar-Kimber,Daniel H. Sterman,Michael Chang,Eun Ha Kang,Mohammed ElBash,Michael Lanuti,Ashraf A. Elshami,Karen Gelfand,James M. Wilson,Larry R. Kaiser,Steven Μ. Albelda	1998	167
11	Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma. PubMed ·John C. Kucharczuk,B. Randazzo,Michael Y. Chang,K M Amin,Ashraf A. Elshami,Daniel H. Sterman,Nabil P. Rizk,Katherine L. Molnar-Kimber,Stuart M. Brown,Alasdair Maclean,Leslie A. Litzky,Nicholas Fraser,Steven Μ. Albelda,Larry R. Kaiser	1997	96
12	Comparison of effects of sirolimus on cytokine dependent and cytokine independent proliferation Inflammation Research ·Katherine L. Molnar-Kimber,A.E. Rhoad,L. Warner,Haoze Chen,Suren N. Sehgal	1995	2
13	A Putative Sirolimus (Rapamycin) Effector Protein Biochemical and Biophysical Research Communications ·Y.Q. Chen,Hao Chen,A.E. Rhoad,L. Warner,Thomas J. Caggiano,A. FAILLI,Hongzhou Zhang,Cheston Hsiao,Kazuki Nakanishi,Katherine L. Molnar-Kimber	1994	59
14	Modulation of TNFα and IL-1β from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors Inflammation Research ·Katherine L. Molnar-Kimber,L. Yonno,Richard J. Heaslip,Barry M. Weichman	1993	55
15	Differential regulation of TNF‐α and IL‐1β production from endotoxin stimulated human monocytes by phosphodiesterase inhibitors Mediators of Inflammation ·Katherine L. Molnar-Kimber,L. Yonno,Richard J. Heaslip,Barry M. Weichman	1992	28
16	Strategies for the development of new antiarthritic agents International Journal of Immunopharmacology ·Alan J. Lewis,Keith B. Glaser,Robert J. Sturm,Katherine L. Molnar-Kimber,C. C. Bansbach	1992	4
17	Adenovirus vaccine vectors expressing hepatitis B surface antigen: Importance of regulatory elements in the adenovirus major late intron Virology ·B B Mason,Alan R. Davis,Bheem M. Brat,Murty Chengalvala,Michael D. Lubeck,Gordon Zandle,Beverley Kostek,Stan Cholodofsky,Surendra K. Dheer,Katherine L. Molnar-Kimber,Satoshi Mizutani,Paul P. Hung	1990	31
18	High level expression of the envelope glycoproteins of the human immunodeficiency virus type I in presence of rev gene using helper-independent adenovirus type 7 recombinants Virology ·Pranab K. Chanda,Robert J. Natuk,B B Mason,Bheem M. Brat,Lynda Greenberg,Surendra K. Dheer,Katherine L. Molnar-Kimber,Satoshi Mizutani,Michael D. Lubeck,Alan R. Davis,Paul P. Hung	1990	32
19	T cell clones with dual specificity for M1s and various major histocompatibility complex determinants. The Journal of Experimental Medicine ·Susan R. Webb,Katherine L. Molnar-Kimber,Jennifer Bruce,Jonathan Sprent,Darcy B. Wilson	1981	55
20	Absence of H-2 restriction in primary and secondary mixed-lymphocyte reactions to strong M1s determinants. The Journal of Experimental Medicine ·Katherine L. Molnar-Kimber,Jonathan Sprent	1980	51

About Katherine L. Molnar-Kimber

Katherine L. Molnar-Kimber is a scholar working on Genetics, Biotechnology and Infectious Diseases, having authored 37 papers that have together received 2.1k indexed citations. Recurring topics across this work include Virus-based gene therapy research (21 papers), Hepatitis B Virus Studies (7 papers), Herpesvirus Infections and Treatments (6 papers), Viral gastroenteritis research and epidemiology (5 papers), Cancer Research and Treatments (5 papers), Signaling Pathways in Disease (5 papers), CAR-T cell therapy research (4 papers) and Viral Infectious Diseases and Gene Expression in Insects (4 papers). The work is most often cited by research in Genetics (1.1k citations), Biotechnology (284 citations) and Oncology (577 citations). Katherine L. Molnar-Kimber has collaborated with scholars based in United States, Canada and Israel. Frequent co-authors include Steven Μ. Albelda, William S. Mason, Larry R. Kaiser, Barry M. Weichman, Jesse Summers, Kunjlata M. Amin, Daniel H. Sterman, James M. Wilson, Jonathan Sprent and Eugene Kang. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and The Journal of Experimental Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact